Redeye initiates coverage of Senzime, a Swedish medtech company specialising in quantitative neuromuscular patient monitoring with its flagship device, the TetraGraph system. With a rapidly expanding installed base and rising utilisation rates, we see a compelling growth trajectory ahead. Our fair value range indicates solid upside potential, with quarterly reports demonstrating solid growth as the primary trigger for the share price.

Läs mer på Redeye